Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q2

4483.TEDINET S100PLQM
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥12.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.3bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥21.8bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥5.0bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥2.2bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥1.7bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥909m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥2.2bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.7bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥908m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥678m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥597m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥677m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥1.1bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥598m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥112.1bnat 2022-09-30Cons.Assets IFRS
Total assets¥62.1bnat 2022-03-31Cons.Assets IFRS
Total assets¥58.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥50.5bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥30.9bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥61.6bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥28.9bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥28.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥61.6bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥28.9bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥41.5bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥15.5bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥3.8bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥21.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥3.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥48.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥25.292022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.762022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥57.742021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥20.262021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥10.642021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥23.862022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.142022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥54.162021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥102021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio55.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.8%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 72
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥189m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥99m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-07-01 → 2022-09-30¥933m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-07-01 → 2022-09-30¥890m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥84m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥192m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-07-01 → 2022-09-30¥144m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-07-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥24m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-07-01 → 2022-09-30¥903m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥924m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-07-01 → 2022-09-30¥485m
—segment totalrevenue2022-04-01 → 2022-09-30¥12.2bn
—segment totalrevenue2022-07-01 → 2022-09-30¥6.4bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥6.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥126m
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥67m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.5bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥88m
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥53m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥88m
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥53m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥157m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥82m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-07-01 → 2021-09-30¥877m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.6bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-07-01 → 2021-09-30¥847m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥56m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥29m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-04-01 → 2021-09-30¥163m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-07-01 → 2021-09-30¥113m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2021-04-01 → 2021-09-30¥5.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2021-07-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-04-01 → 2021-09-30¥5.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-07-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥31m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥23m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-07-01 → 2021-09-30¥877m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2021-07-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2021-07-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2021-04-01 → 2021-09-30¥730m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2021-07-01 → 2021-09-30¥400m
—segment totalrevenue2021-04-01 → 2021-09-30¥9.6bn
—segment totalrevenue2021-07-01 → 2021-09-30¥5.1bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥9.6bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥5.0bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥88m
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥53m
—segment totalsegment profit2021-04-01 → 2021-09-30¥2.6bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 883
ItemContextValueUnit
Dividends ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-565000000JPY
Dividends ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-565000000JPY
Dividends ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Dividends ss IFRSCurrentYTDDuration-565000000JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-15000000JPY
Increase decrease by business combination ss IFRSCurrentYTDDuration-15000000JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-6000000JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember6000000JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember－JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Transfer to retained earnings ss IFRSCurrentYTDDuration－JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember4000000JPY
Total transactions with owners IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-558000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember29018000000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-15000000JPY
Total transactions with owners IFRSCurrentYTDDuration29002000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember27000000JPY
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember10466000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember61638000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember-28000000JPY
Equity IFRSCurrentQuarterInstant61610000000JPY
Profit loss before tax IFRSPrior1YTDDuration1715000000JPY
Profit loss before tax IFRSCurrentYTDDuration2234000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration750000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration936000000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration329000000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration616000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration3000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-24000000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-667000000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration-1244000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-304000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration232000000JPY
Subtotal ope cf IFRSPrior1YTDDuration1826000000JPY
Subtotal ope cf IFRSCurrentYTDDuration2751000000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration13000000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration0JPY
Interest paid ope cf IFRSPrior1YTDDuration-28000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-39000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-731000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-1029000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration1079000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration1682000000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-164000000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-1147000000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-372000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass